Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "credit fc26 Visitez le site Buyfc26coins.com La référence incontestée pour les FC 26 coins.VIiF"

Looking for quality documents?
external link icon
Repligen Corporation to Present at Barclays Global Healthcare Conference
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our
external link icon
Repligen Launches New Products in OPUS™ Line of Pre-Packed Chromatography Columns
external link icon
Repligen Announces Conference Call to Update Orencia® Lawsuit Tuesday, April 8th, 9:00 a.m. EST
publications icon
KB20002 Methods to Access QVCA Software during Qualification Services Article
publications icon
DOC0436 ZipChip Brochure Accelerate your MS Characterization
external link icon
Repligen Opens Training & Innovation Center to Elevate Customer Experience
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. The opening celebration, held on the evening of September 23, attracted a group of over 150 biopharma and CDMO customers. The RTIC buildout, which features product exhibits, purpose-built demonstration areas and technical training space, was designed to provide customers with pre- and post-sales support, and provide a hands-on experience with Repligen’s innovative bioprocessing solutions. The RTIC enables the functional display of all Repligen bioprocessing technologies; a complete collection from across the company’s global manufacturing sites. Upstream intensification technologies include XCell ® ATF and KrosFlo ® TFDF ® devices and controllers. Downstream products include OPUS ® pre-packed chromatography
external link icon
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, Feb. 18, at 3:00 p.m. EST. A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug
external link icon
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion
event icon
The Impact of Emerging Upstream and Downstream Technologies on Process Productivity and Economics
Presented at Biotech Week Boston, learn how Repligen emerging technologies are impacting upstream and downstream bioprocessing practrices and processes. September 27, 2017 | 31 minutes
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support